文献速递神经MR

3T场强下应用增强后Dixon uT1RESS与MPRAGE序列前瞻性对比脑肿瘤检出与表征

Prospective comparison of brain tumor detection and characterization using post-contrast Dixon uT1RESS and MPRAGE at 3 Tesla.
PubMed 文献 · Eur J Radiol · 2025-07-05

单中心前瞻性研究纳入20例原发性脑肿瘤和脑转移瘤患者,在3T场强下对比Dixon uT1RESS与MPRAGE序列的图像质量和病灶表征。Dixon uT1RESS采集时间更短(2分51秒 vs 4分52秒),对比噪声比和肿瘤-脑对比度显著更高(p < 0.001),主观总体图像质量相似,病灶显示更明显、边界更清晰(p < 0.001),但MPRAGE在评估病灶内部结构方面更优(p < 0.05);Dixon uT1RESS额外检出3个病灶。作者认为该技术为改善脑肿瘤成像提供了有前景的潜力,但全面病灶表征可能仍需其他序列。

要点

  • Dixon uT1RESS采集时间2分51秒,短于MPRAGE的4分52秒,对比噪声比和肿瘤-脑对比度均显著更高(p < 0.001)。
  • Dixon uT1RESS病灶显示更明显、边界更清晰(p < 0.001),并额外检出3个病灶,尤其对小转移灶。
  • MPRAGE在评估病灶内部结构方面更优(p < 0.05),全面表征可能仍需其他序列。

核心结论

  • Dixon uT1RESS显著提高了肿瘤明显度和检出率,尤其对小转移灶,为脑肿瘤成像提供了有前景的潜力,但全面病灶表征可能仍需其他序列。

研究设计与样本

  • 单中心前瞻性研究,纳入20例原发脑肿瘤和脑转移瘤患者(12名男性,年龄35-83岁),在3T场强下采集MPRAGE和Dixon uT1RESS序列,以客观指标(对比噪声比、肿瘤-脑对比度、肿瘤体积)和两名独立读者的主观评分进行评估,采用Wilcoxon符号秩检验比较差异。

关键影像表现/征象

  • Dixon uT1RESS的对比噪声比和肿瘤-脑对比度显著高于MPRAGE(p < 0.001)。
  • Dixon uT1RESS病灶显示更明显、边界更清晰(p < 0.001)。
  • MPRAGE在评估病灶内部结构方面优于Dixon uT1RESS(p < 0.05)。
  • Dixon uT1RESS额外检出3个病灶。
  • 两序列主观总体图像质量相似。

诊断标准与关键数值

  • 客观图像质量以对比噪声比、肿瘤-脑对比度和肿瘤体积评估,Dixon uT1RESS的对比噪声比和肿瘤-脑对比度显著高于MPRAGE(p < 0.001)。
  • 主观图像质量由两名独立读者评估病灶可见性、病灶边缘、运动和静止伪影。
  • 并排比较评估病灶检出、内部结构评估及血管或硬脑膜侵犯的诊断性能。
  • Dixon uT1RESS采集时间2分51秒,MPRAGE为4分52秒。

临床应用与阅片要点

  • Dixon uT1RESS可在更短采集时间内提供更高的肿瘤对比度和更清晰的病灶边缘,有助于病灶检出,尤其对小转移灶。
  • 评估病灶内部结构时MPRAGE可能更优,全面病灶表征可能仍需其他序列。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This study aimed to evaluate the image quality and lesion characterization with Dixon unbalanced T1 relaxation-enahnced steady-state (uT1RESS) in comparison to magnetization-prepared rapid acquisition gradient echo (MPRAGE) pulse sequence for detecting brain tumors, focusing on its potential to improve diagnostic accuracy and enhance brain tumor assessment.

METHODS: This single-center prospective study enrolled 20 patients (12 males, aged 35-83), with primary brain tumors and brain metastases. Both MPRAGE and Dixon uT1RESS were acquired at 3 T. Objective image quality was assessed by contrast-to-noise ratio (CNR), tumor-to-brain contrast, and tumor volume. Subjective image quality was assessed by two independent readers focusing on lesion visibility, lesion margins, motion, and static artifacts. A side-by-side comparison assessed diagnostic performance regarding lesion detection, evaluation of internal structure and vascular or dural invasion.

RESULTS: Dixon uT1RESS had a reduced acquisition time (2 min 51 s vs. 4 min 52 s for MPRAGE) and showed significantly higher CNR and tumor-to-brain contrast compared to MPRAGE (p < 0.001). Subjectively, both sequences showed similar overall image quality. Dixon uT1RESS achieved more conspicuous lesions with better-defined lesion margins (p < 0.001), while MPRAGE performed better in evaluating internal lesion structure (p < 0.05). Dixon uT1RESS was rated better for lesion detection, with three lesions additionally identified on this sequence. Wilcoxon signed-rank test was used to assess differences.

CONCLUSIONS: Dixon uT1RESS significantly improved tumor conspicuity and detection, particularly for small metastatic lesions. This new technique offers promising potential for enhancing clinical brain tumor imaging, though additional sequences may be necessary for comprehensive lesion characterization.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Tóth A, Edelman RR, Hagar MT, et al. Prospective comparison of brain tumor detection and characterization using post-contrast Dixon uT1RESS and MPRAGE at 3 Tesla. Eur J Radiol. 2025. PMID: 40645026. doi:10.1016/j.ejrad.2025.112283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。